Letter | Published:

Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides

Nature volume 528, pages 123126 (03 December 2015) | Download Citation


Copy number variations have been frequently associated with developmental delay, intellectual disability and autism spectrum disorders1. MECP2 duplication syndrome is one of the most common genomic rearrangements in males2 and is characterized by autism, intellectual disability, motor dysfunction, anxiety, epilepsy, recurrent respiratory tract infections and early death3,4,5. The broad range of deficits caused by methyl-CpG-binding protein 2 (MeCP2) overexpression poses a daunting challenge to traditional biochemical-pathway-based therapeutic approaches. Accordingly, we sought strategies that directly target MeCP2 and are amenable to translation into clinical therapy. The first question that we addressed was whether the neurological dysfunction is reversible after symptoms set in. Reversal of phenotypes in adult symptomatic mice has been demonstrated in some models of monogenic loss-of-function neurological disorders6,7,8, including loss of MeCP2 in Rett syndrome9, indicating that, at least in some cases, the neuroanatomy may remain sufficiently intact so that correction of the molecular dysfunction underlying these disorders can restore healthy physiology. Given the absence of neurodegeneration in MECP2 duplication syndrome, we propose that restoration of normal MeCP2 levels in MECP2 duplication adult mice would rescue their phenotype. By generating and characterizing a conditional Mecp2-overexpressing mouse model, here we show that correction of MeCP2 levels largely reverses the behavioural, molecular and electrophysiological deficits. We also reduced MeCP2 using an antisense oligonucleotide strategy, which has greater translational potential. Antisense oligonucleotides are small, modified nucleic acids that can selectively hybridize with messenger RNA transcribed from a target gene and silence it10,11, and have been successfully used to correct deficits in different mouse models12,13,14,15,16,17,18. We find that antisense oligonucleotide treatment induces a broad phenotypic rescue in adult symptomatic transgenic MECP2 duplication mice (MECP2-TG)19,20, and corrected MECP2 levels in lymphoblastoid cells from MECP2 duplication patients in a dose-dependent manner.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions

Gene Expression Omnibus

Data deposits

RNA-seq data have been deposited in the Gene Expression Omnibus under accession number GSE71235.


  1. 1.

    & CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148, 1223–1241 (2012)

  2. 2.

    et al. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur. J. Hum. Genet. 17, 444–453 (2009)

  3. 3.

    MECP2 duplication syndrome. Mol. Syndromol. 2, 128–136 (2011)

  4. 4.

    , & The MECP2 duplication syndrome. Am. J. Med. Genet. A. 152A, 1079–1088 (2010)

  5. 5.

    et al. XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28. Am. J. Med. Genet. 85, 243–248 (1999)

  6. 6.

    et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526–530 (2002)

  7. 7.

    et al. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nature Med. 14, 843–848 (2008)

  8. 8.

    et al. Correction of fragile X syndrome in mice. Neuron 56, 955–962 (2007)

  9. 9.

    , , , & Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143–1147 (2007)

  10. 10.

    , , & Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 18, 634–643 (2012)

  11. 11.

    & RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259–293 (2010)

  12. 12.

    et al. Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nature Med. 19, 345–350 (2013)

  13. 13.

    et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111–115 (2012)

  14. 14.

    et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123–126 (2011)

  15. 15.

    et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409–412 (2015)

  16. 16.

    et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74, 1031–1044 (2012)

  17. 17.

    et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18 (2011)

  18. 18.

    et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290–2296 (2006)

  19. 19.

    et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679–2689 (2004)

  20. 20.

    et al. Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nature Genet. 44, 206–211 (2012)

  21. 21.

    et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224–1229 (2008)

  22. 22.

    , , , & Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum. Mol. Genet. 18, 2431–2442 (2009)

  23. 23.

    et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263–269 (2010)

  24. 24.

    et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69, 905–914 (1992)

  25. 25.

    et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386–389 (1998)

  26. 26.

    et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genet. 19, 187–191 (1998)

  27. 27.

    & MeCP2: only 100% will do. Nature Neurosci. 15, 176–177 (2012)

  28. 28.

    et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nature Genet. 1, 159–165 (1992)

  29. 29.

    et al. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am. J. Hum. Genet. 80, 633–649 (2007)

  30. 30.

    et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595–600 (2006)

  31. 31.

    , & Anxiety-related behaviors in the elevated zero-maze are affected by genetic factors and retinal degeneration. Behav. Neurosci. 115, 468–476 (2001)

  32. 32.

    et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013)

  33. 33.

    , & HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015)

  34. 34.

    & Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010)

  35. 35.

    & The Mouse Brain in Stereotaxic Coordinates (Academic, 2001)

  36. 36.

    et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503, 72–77 (2013)

  37. 37.

    et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J. Neurosci. 31, 700–711 (2011)

Download references


We thank R. Jaenisch for the Mecp2tm1Jae mice, S. Chun for ASOs tolerability studies in wild-type mice, L. Lombardi, M. Rousseaux, C. Alcott and V. Brandt for critical input, and C. Spencer for behavioural assays training. We are indebted to the patients and families who participated in this study. This project was funded by the National Institutes of Health (5R01NS057819 and 5P30HD024064 to H.Y.Z.), the Rett Syndrome Research Trust (401 Project), the Carl. C. Anderson, Sr and Marie Jo Anderson Charitable Foundation, the Howard Hughes Medical Institute (H.Y.Z.), NSF DMS-1263932 (Z.L.), and the Baylor Intellectual Disabilities Research Center (1U54HD083092) neurovisualization, neuroconnectivity and neurobehavioral cores.

Author information


  1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA

    • Yehezkel Sztainberg
    •  & Huda Y. Zoghbi
  2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, Texas 77030, USA

    • Yehezkel Sztainberg
    • , Shuang Hao
    • , Bin Tang
    • , Zhenyu Wu
    • , Jianrong Tang
    • , Ying-Wooi Wan
    • , Zhandong Liu
    •  & Huda Y. Zoghbi
  3. The Cain Foundation Laboratories, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, Texas 77030, USA

    • Hong-mei Chen
    •  & John W. Swann
  4. Department of Neuroscience, Baylor College of Medicine, Houston, Texas 77030, USA

    • Hong-mei Chen
    •  & John W. Swann
  5. Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA

    • Hong-mei Chen
    • , John W. Swann
    • , Shuang Hao
    • , Bin Tang
    • , Zhenyu Wu
    • , Jianrong Tang
    • , Zhandong Liu
    •  & Huda Y. Zoghbi
  6. Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas 77030, USA

    • Ying-Wooi Wan
  7. Isis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USA

    • Frank Rigo
  8. Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas 77030, USA

    • Huda Y. Zoghbi


  1. Search for Yehezkel Sztainberg in:

  2. Search for Hong-mei Chen in:

  3. Search for John W. Swann in:

  4. Search for Shuang Hao in:

  5. Search for Bin Tang in:

  6. Search for Zhenyu Wu in:

  7. Search for Jianrong Tang in:

  8. Search for Ying-Wooi Wan in:

  9. Search for Zhandong Liu in:

  10. Search for Frank Rigo in:

  11. Search for Huda Y. Zoghbi in:


Y.S. performed the behavioural and molecular experiments. Y.S., H.C., J.W.S., J.T., F.R. and H.Y.Z. contributed to the concept and design of the experiments. H.C. performed the electrophysiological (LTP) experiments. S.H., Z.W. and B.T. performed the EEG experiments. Y.S., H.C., J.W.S., F.R., Y.-W.W., Z.L., S.H., J.T. and H.Y.Z. collected, analysed and interpreted the data. Y.S. and H.Y.Z. wrote and edited the paper.

Competing interests

F.R. is an employee of Isis Pharamaceuticals.

Corresponding author

Correspondence to Huda Y. Zoghbi.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Figures 1-4

    This file contains Supplementary Figures 1-4, which show the original uncropped western blots as follows: (1) Figure 1c,d; (2) Figure 3e,d; (3) Extended Data Figure 1b; and (4) Extended Data Figure 5c,d. The black frames denote how the gels were cropped for the final figure.

Excel files

  1. 1.

    Supplementary Table 1

    This table contains RNA-seq results from the genetic rescue experiment. Only the genes with expression significantly different between the groups are presented.

  2. 2.

    Supplementary Table 2

    This table contains RNA-seq results from the antisense oligonucleotides experiments. Only the genes with expression significantly different between the groups are presented.


  1. 1.

    Spontaneous seizure of MECP2 duplication transgenic mouse

    This video shows a spontaneous seizure from a 30-week old male MECP2 duplication transgenic mouse during EEG recording.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.